
AI-generated summary
Researchers are exploring novel therapeutic applications of psychedelics in mental health treatment, particularly for depression, building on both clinical research and traditional indigenous practices.
Researchers are looking at new ways to use psychedelics to treat depression. Science journalist Marcelo Leite says there's also a lot to learn from indigenous people who have used them for generations.
NPR does not offer or accept money for coverage or interviews.
Anyone who makes such an offer or request is not an NPR employee and does not represent NPR.

Jeff La Marca, a 68-year-old Medicare beneficiary in New Jersey, was denied access to a new $50 monthly Medicare pilot program for GLP-1 weight-loss drugs because his severe sleep apnea routes him back to standard Part D plans with much higher costs.

The FDA has authorized Juul Labs to sell an updated version of its e-cigarette, Juul2, featuring an optional age-verification system to prevent underage use. The decision allows the company to market a new device after years of regulatory scrutiny, lawsuits, and declining teen vaping rates. Regulators emphasize the product is for adult smokers seeking to quit, not for non-smokers.

Psychologist Diana Hill explains body image flexibility as a way to cope with negative thoughts about appearance without requiring self-love, offering practical exercises to redirect focus from looks to internal awareness, bodily functionality, and values-driven actions amid societal pressures from weight loss drugs and social media.

The FDA has approved Gilead's Bixlenvo, a once-daily HIV pill combining bictegravir and lenacapavir. Designed for patients with suppressed virus who require complex regimens or seek alternatives, it aims to simplify treatment and preserve future options.

Health Secretary Robert F. Kennedy Jr. has posted anti-vaccine misinformation on social media following the first measles-linked deaths in Pennsylvania in 35 years, which included a newborn baby.

Medicare's Bridge program, which provides obesity drugs for $50 monthly, has seen significant uptake with CVS and Walgreens filling 200,000 prescriptions in under two months. The pilot aims to improve health outcomes for eligible seniors through 2027.